slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Executive Summary PowerPoint Presentation
Download Presentation
Executive Summary

Loading in 2 Seconds...

play fullscreen
1 / 6

Executive Summary - PowerPoint PPT Presentation


  • 110 Views
  • Uploaded on

Executive Summary. Platform Technology (TSCP): Fusion proteins with two functional ends First-in-class drugs to convert inter-cellular signals Studied for a decade / Multiple scientific publications Wide IP estate licensed from the University of Pennsylvania Products

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Executive Summary' - rance


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Executive Summary

  • Platform Technology (TSCP):
    • Fusion proteins with two functional ends
    • First-in-class drugs to convert inter-cellular signals
    • Studied for a decade / Multiple scientific publications
    • Wide IP estate licensed from the University of Pennsylvania
  • Products
    • Pipeline: Four TSCP fusion combinations
    • Two products in pre-clinical development
    • Autoimmune indications with unmet needs
    • KAHR-101
      • Complete production process developed
      • Efficacy demonstrated in multiple animal disease models
      • Clinical trials expected in 2010 in RA patients
slide2

Company Information

  • Hadasit Bio-Holdings (“HBL”, TASE: HDST) portfolio company
  • Located in Israel
  • Operations initiated mid 2007
  • Platform technology; ‘Trans signal converter proteins (TSCP)’. Licensed from the University of Pennsylvania
  • Leading products: KAHR-101 & KAHR-102 for the treatment of autoimmune diseases
slide3

Team

  • CEO – Dr. Noam Shani, Ph.D. Previous VP-R&D for Medgenics (AIM: MEDG) and for Compugen (NASDAQ: CGEN)
  • Research Officer- Dr. Michal Dranitzki Elhalel, M.D. Senior physician and scientist at the Hadassah Medical Center. Investigating the TSCP technology since 2000
  • Scientific Advisory Board
    • Prof. Marc Feldmann, M.D., Ph.D. Head, Kennedy Institute of Rheumatology - Imperial College, London. Developed Ramicade (J&J)
    • Prof. Lawrence Steinman, M.D. Chair of Immunology at Stanford University. Developed Tysabri (Biogen-Idec)
    • Dr. Nabil Hanna, Ph.D. Previous Executive Vice President Research, Biogen-Idec. Developed Rituximab and Zevalin (Biogen-Idec)
    • Prof. Mark Tykocinski, M.D. Dean, Jefferson Medical College, Philadelphia. Inventor of the TSCP platform technology
slide4

Platform Technology: TSCP

  • Represents the third generation of protein-based therapeutics
    • First generation: Protein with one functional unit and one target (e.g. IFN, EPO, hGH)
    • Second generation: Protein with twofunctional units and one target (e.g. mAb, Fc-fusions)
    • Third generation: Protein with twofunctional units and two targets (TSCP molecules)
  • Fusion proteins with Two functional ends
  • Both sides transmit different and complementary intercellular or intracellular signals
  • Intensely studied for a decade, mostly by U. Penn and Hadassah teams
  • Drug potential documented in multiple scientific publications *
  • IP was licensed from U. Penn

* See website for scientific publications – www.kahr-medical.com

slide6

KAHR Opportunity

  • Technological breakthrough – TSCP platform technology
  • Huge market with unmet clinical needs
  • Competitive advantage over existing paradigm
  • Robust development pipeline
  • Strong IP portfolio
  • Seasoned team
  • KAHR has initiated a series-A financing round and is seeking strategic investments, licensing and co-development collaborations